Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedaquiline-containing short-course regimen for multidrug-resistant tuberculosis
ChiCTR2000029012Phase 4Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bedaquiline, levofloxacin, linezolid, clofazimine and d-cycloserine in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Treatment success rate. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
bedaquilinelevofloxacinlinezolidclofazimined-cycloserine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on ChiCTR2000029012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029012.